BioSpace News Archive

Viking Therapeutics, Inc. today announced the completion of patient enrollment in its Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference.

Opticyte Earns FDA Breakthrough Device Designation for the First Cell O 2 Patient Monitor for Organ Failure.

Schrödinge , Inc. today provided an update on its progress across the business and announced its strategic priorities for 2023.

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 48 programs in development, including 36 programs in clinical trials encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities.

Context Therapeutics Inc. and Lonza today announced that the companies are collaborating to manufacture CTIM-76, Context’s clinical development candidate.

BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd.

GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, provided updates on its business and highlighted key upcoming milestones.

Elevation Oncology, Inc. today announced that Joseph Ferra , Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 9:45 am PT.

Small Pharma Inc. today confirms that the first patient has been dosed in its Phase I study comparing the profiles of intramuscular (“ IM ”) and intravenous (“ IV ”) , the Company’s proprietary formulation of N, N-dimethyltryptamine (“ DMT ”).